Low-dose radiotherapy (LDRT) is gaining attention as a novel therapeutic approach for central nervous system (CNS) pathologies with inflammatory components, including Alzheimer's disease (AD) and other neurodegenerative disorders. This webinar, "Low Dose Radiotherapy (LDRT): Is There an Emerging Role in the Central Nervous System?", examines LDRT's potential to modulate key pathological features such as neuroinflammation, amyloid plaque accumulation, and hyperphosphorylated tau across various CNS conditions. Preclinical studies show that LDRT reduces amyloid burden, normalizes inflammatory markers like TSPO and CLUSTERIN, and enhances synaptic protein expression in animal models. Early human trials, using regimens like 10 Gy in 5 fractions, demonstrate good tolerability with minimal side effects, such as transient epilation, and suggest cognitive stabilization or improvement in AD patients. Ongoing randomized controlled trials are evaluating diverse LDRT dosing strategies, from ultra-low (24 cGy/6 fractions) to conventional low doses (300 cGy/6 fractions), focusing on cognitive outcomes and biomarker changes across inflammatory CNS disorders. While the mechanisms and long-term safety of LDRT remain under investigation, emerging evidence supports its potential as a versatile treatment approach. This session will review current findings and explore LDRT's broader applications in managing CNS pathologies with inflammatory components.